PL116307B2 - Process for the preparation of vaccine for immunizationof animals with human globulins - Google Patents

Process for the preparation of vaccine for immunizationof animals with human globulins Download PDF

Info

Publication number
PL116307B2
PL116307B2 PL21042878A PL21042878A PL116307B2 PL 116307 B2 PL116307 B2 PL 116307B2 PL 21042878 A PL21042878 A PL 21042878A PL 21042878 A PL21042878 A PL 21042878A PL 116307 B2 PL116307 B2 PL 116307B2
Authority
PL
Poland
Prior art keywords
vaccine
preparation
animals
immunizationof
human
Prior art date
Application number
PL21042878A
Other languages
Polish (pl)
Other versions
PL210428A1 (en
Inventor
Slaw Polak
Zofia Marzec
Kazimierz Lawniczak
Original Assignee
Wojewodzka Stacja Krwiodawstwa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wojewodzka Stacja Krwiodawstwa filed Critical Wojewodzka Stacja Krwiodawstwa
Priority to PL21042878A priority Critical patent/PL116307B2/en
Publication of PL210428A1 publication Critical patent/PL210428A1/en
Publication of PL116307B2 publication Critical patent/PL116307B2/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Description

Przedmiotem wynalazku jest sposób wytwarzania szczepionki do immunizowania zwierzat globulinami ludzkimi celem uzyskania poliwalentnej surowicy antyglobulinowej znajdujacej zastosowanie do odczynu antyglobulinowego Coombsa, w wykrywaniu swoistych niekompletnych przeciwcial zaabsorbowanych na krwinkach.Dotychczasowy sposób immunizowania zwierzat polegal na wstrzykiwaniu królikom, kozom i owcom ludzkich surowic o wysokim mianie alloprzeciwcial anty-A i anty-B, wzglednie wyizolowanych z surowicy ludzkiej globulin. Sposoby te opisane sa w ksiazce pt.: „Przepisy dla Stacji i Punktów Krwiodawstwa* dotyczace wytwarzania krwi i preparatów krwiopochodnych" PZWL Warszawa 1974r.Stosujac dotychczasowe sposoby immunizacji nie udalo sie uzyskac poliwalentnej surowicy antyglobuli¬ nowej konia.Celem wynalazku jest uzyskanie szczepionki, która w procesie immunizacji koni umozliwi otrzymanie surowicy odpornosciowej, zawierajacej przeciwciala antyglobulinowe poliwalentne i wysoce aktywne.W sposobie wedlug wynalazku surowice odpornosciowa konska miesza sie z równa objetoscia ludzkiej surowicy i inkubuje sie w temp. +37°C przez 2 godziny, nastepnie w temp. +4°C przez 24 godziny. Po odwirowaniu otrzymany osad (kompleks — antygen —przeciwcialo) zawiesza sie w roztworze 0,15 M NaCl i ogrzewa w temp. +80?C przez 10 minut. Tak przygotowana szczepionke stosuje sie do szczepienia koni dotychczas nie immunizowanych.Otrzymana surowica odpornosciowa w wyniku szczepienia koni wyzej opisana szczepionka, po inakty- wacji w +56°C przez 1 godzine — moze byc przechowywana w temp. —20°C przez kilka lat.Przyklad. Na kolumnie Sephadexu G 200 wyizolowano z surowicy ludzkiej bialko o ciezarze cza¬ steczkowym wiekszym od 200000 a na Sephadexie DEAE — A 50 wyizolowano z surowicy ludzkiej immu- noglobuliny klasy G. Uzyskanymi —jak wyzej ^frakcjami bialkowymi szczepiono konie domiesniowo wprowadzajac w jednym wstrzyknieciu okolo 50mg bialka z lOml kompletnego adjuventu Freunda.Przeprowadzono 3 cykle szczepien po 5 injekcji wykonywanych w odstepach tygodniowych na kazdy * cykl szczepien. Przerwa pomiedzy poszczególnymi cyklami szczepien wynosila 2 tygodnie. W powyzszy sposób otrzymano surowice odpornosciowa przeciw globulinom ludzkim. Surowice te zmieszano z równa objetoscia ludzkiej surowicy i inkubowano w temp. +37°C przez 2 godz., nastepnie w temp. +4° przez 24 godziny. Po odwirowaniu otrzymany osad zawieszano w roztworze 0,15 MNaCl i ogrzewano w temp. +80°C przez 10 minut.2 116 307 Przygotowana powyzszym sposobem szczepionke wstrzykiwano koniom domiesniowo w ilosci ok. 20mg bialka na jedna injekcje z lOml kompletnego adjuwantu Freunda. Przeprowadzono 5 cykli szczepien po 4 injekcje na cykl, podawane w odstepach tygodniowych i 10 cykli po 2 injekcje. Przerwa pomiedzy cyklami szczepien wynosila 2 tygodnie.Po immunizacji przeprowadzonej powyzszym sposobem uzyskano konska swoista, poliwalentna suro¬ wice antyglobulinowa, wysoce aktywna, która w rozcienczeniu od 1:80 do 1 : 120 daje wyrazne reakcje serologiczne z krwinkami oplaszczonymi przeciwcialami dla ukladu Rh, Kell, Cellano, Le, Fy, Jk is.Zastrzezenie patentowe Sposób wytwarzania szczepionki do immunizowania zwierzat, zwlaszcza koni, znamienny tym, ze surowice odpornosciowa konska miesza sie z surowica ludzka w stosunku 1: 1 i inkubuje w temperaturze 4°C przez 24h, po czym otrzymany precypitat odwirowuje sie i zawiesza w roztworze 0,15 M NaCl i ogrzewa w temperaturze 80°C przez 10 minut.' Prac. Poligraficzna UP PRL. Naklad 120 egz.Cena 100 zl. PLThe subject of the invention is a method for the preparation of a vaccine for immunizing animals with human globulins in order to obtain a polyvalent antiglobulin serum applicable to the Coombs antiglobulin test, in the detection of specific incomplete antibodies absorbed on blood cells. anti-A and anti-B, relatively isolated from human serum globulins. These methods are described in the book: "Recipes for Blood Donation Stations and Points * for the production of blood and blood products" PZWL Warsaw 1974. Using the current methods of immunization, it was not possible to obtain a polyvalent antiglobula serum of the horse. The aim of the invention is to obtain a vaccine that in the process of immunization of horses it will enable the preparation of immune serum containing polyvalent and highly active antiglobulin antibodies. In the method according to the invention, equine immune sera is mixed with an equal volume of human serum and incubated at + 37 ° C for 2 hours, then at + 4 ° C for 24 hours After centrifugation, the obtained pellet (antigen-antibody complex) is suspended in 0.15 M NaCl solution and heated at +80 ° C for 10 minutes. Immune serum obtained as a result of vaccinating horses with the above-described vaccine, after inactivation at +5 6 ° C for 1 hour - can be stored at -20 ° C for several years. Example. On the Sephadex G 200 column, a protein with a molecular weight greater than 200,000 was isolated from human serum, and DEAE-A 50 was isolated from human serum with class G immunoglobulin on the Sephadex G 200 column. The horses were inoculated intramuscularly with one injection in one injection about approx. 50mg of protein with 10ml of Freund's complete adjuvant. 3 vaccination cycles with 5 weekly injections for each * vaccination course were performed. The interval between individual vaccination cycles was 2 weeks. Human globulin immune sera were obtained as above. These sera were mixed with an equal volume of human serum and incubated at + 37 ° C for 2 hours, then at + 4 ° C for 24 hours. After centrifugation, the obtained pellet was suspended in 0.15 MNaCl solution and heated at + 80 ° C for 10 minutes.2 116 307 The vaccine prepared as above was injected into horses intramuscularly in the amount of about 20 mg of protein per one injection with 10 ml of complete Freund's adjuvant. 5 vaccination cycles were carried out with 4 injections per cycle, administered at weekly intervals and 10 cycles with 2 injections. The interval between vaccination cycles was 2 weeks. After immunization carried out by the above method, horses were obtained specific, polyvalent antiglobulin serum, highly active, which at a dilution from 1:80 to 1: 120 gave clear serological reactions with blood cells coated with antibodies to the Rh, Kell system. , Cellano, Le, Fy, Jk is. Patent claim A method of producing a vaccine for immunizing animals, especially horses, characterized in that equine immune sera is mixed with human serum in a ratio of 1: 1 and incubated at 4 ° C for 24h, after The obtained precipitate is then centrifuged and suspended in 0.15 M NaCl solution and heated at 80 ° C for 10 minutes. Wash. Printing of the UP PRL. Mintage 120 copies Price PLN 100. PL

Claims (1)

1. Zastrzezenie patentowe Sposób wytwarzania szczepionki do immunizowania zwierzat, zwlaszcza koni, znamienny tym, ze surowice odpornosciowa konska miesza sie z surowica ludzka w stosunku 1: 1 i inkubuje w temperaturze 4°C przez 24h, po czym otrzymany precypitat odwirowuje sie i zawiesza w roztworze 0,15 M NaCl i ogrzewa w temperaturze 80°C przez 10 minut. ' Prac. Poligraficzna UP PRL. Naklad 120 egz. Cena 100 zl. PL1. Patent claim A method of producing a vaccine for immunizing animals, especially horses, characterized in that equine immune sera is mixed with human serum in the ratio 1: 1 and incubated at 4 ° C for 24 hours, after which the obtained precipitate is centrifuged and suspended in 0.15 M NaCl solution and heated at 80 ° C for 10 minutes. 'Work. Printing of the UP PRL. Mintage 120 copies. Price PLN 100. PL
PL21042878A 1978-10-21 1978-10-21 Process for the preparation of vaccine for immunizationof animals with human globulins PL116307B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL21042878A PL116307B2 (en) 1978-10-21 1978-10-21 Process for the preparation of vaccine for immunizationof animals with human globulins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL21042878A PL116307B2 (en) 1978-10-21 1978-10-21 Process for the preparation of vaccine for immunizationof animals with human globulins

Publications (2)

Publication Number Publication Date
PL210428A1 PL210428A1 (en) 1979-08-27
PL116307B2 true PL116307B2 (en) 1981-06-30

Family

ID=19992153

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21042878A PL116307B2 (en) 1978-10-21 1978-10-21 Process for the preparation of vaccine for immunizationof animals with human globulins

Country Status (1)

Country Link
PL (1) PL116307B2 (en)

Also Published As

Publication number Publication date
PL210428A1 (en) 1979-08-27

Similar Documents

Publication Publication Date Title
Lehner et al. Association between HLA-DR antigens and helper cell activity in the control of dental caries
Haustein et al. Immunoglobulin of T lymphoma cells. Biosynthesis, surface representation, and partial characterization
Preis et al. A single-step immunization by sustained antigen release
Milich et al. Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg). IV. Distinct H-2-linked Ir genes control antibody responses to different HBsAg determinants on the same molecule and map to the IA and IC subregions.
Kanai et al. Naturally-occurring antibodies to poly (ADP-ribose) in patients with systemic lupus erythematosus
Pierce IMMUNE RESPONSES IN VITRO: II. Suppression of the Immune Response in Vitro by Specific Antibody
AU677573B2 (en) Vaccine comprising part of constant region of IgE for treatment of IgE-mediated allergic reactions
Johnson et al. Haptenic properties of paralytic shellfish poison conjugated to proteins by formaldehyde treatment
Pierce et al. The role of macrophages in antibody responses in vitro
Rubin et al. THE IMMUNE RESPONSE AGAINST HAPTEN-AUTOLOGOUS PROTEIN CONJUGATES IN THE MOUSE: III. Specificity of Cooperating Non-Thymus-Processed (B) and Thymus-Processed (T) Lymphocytes
Howard et al. Induction of B cell tolerance to polysaccharides by exhaustive immunization and during immunosuppression with cyclophosphamide
Kochoumian et al. Preparation and immunochemical properties of methoxypolyethylene glycol-coupled and N-carboxymethylated derivatives of ragweed pollen allergen, antigen E
Ivanyi Polymorphism of chicken serum allotypes
Hamaoka et al. Antibody production in mice: IV. The suppressive effect of anti-hapten and anti-carrier antibodies on the recognition of hapten-carrier conjugate in the secondary response
Binz et al. Cellular receptors: binding of radioactively labeled anti-alloantiserum
Parish et al. The tolerance inducing properties in rats of bacterial flagellin cleaved at the methionine residues
Kapp et al. H-2 linked Ir gene control of antibody responses to porcine insulin: I. Development of insulin-specific antibodies in some but not all nonresponder strains injected with proinsulin
Jørgensen et al. T helper lymphocytes recognize the VL domain of the isologous mouse myeloma protein 315
Jou et al. Coupling of protein antigens to erythrocytes through disulfide bond formation: preparation of stable and sensitive target cells for immune hemolysis.
PL116307B2 (en) Process for the preparation of vaccine for immunizationof animals with human globulins
Plescia [174] Preparation and assay of nucleic acids as antigens
De Carvalho et al. Influence of splenectomy in rats on the formation of 19S and 7S antibodies
Gengozian Analysis of serum from lethally irradiated mice treated with rat bone marrow
Pride et al. Mimicry of the a determinant of hepatitis B surface antigen by an antiidiotypic antibody. I. Evaluation in hepatitis B surface antigen responder and nonresponder strains.
Morris The transmission of anti-Brucella abortus agglutinins across the gut in young rats